ArticleMikrochimica acta2020
Hierarchical multifunctional graphene oxide cancer nanotheranostics agent for synchronous switchable fluorescence imaging and chemical therapy.
Article in Mikrochimica acta, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 28 citations in OpenAlex.
- Advances in the Application of Graphene and Its Derivatives in Drug Delivery Systems.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Penicillin and Oxacillin Loaded on PEGylated-Graphene Oxide to Enhance the Activity of the Antibiotics against Methicillin-ResistantPharmaceutics · 2022Article
- Aptamer-based biosensors and application in tumor theranostics.Cancer science · 2022Review
- Advances in Drug Delivery Nanosystems Using Graphene-Based Materials and Carbon Nanotubes.Materials (Basel, Switzerland) · 2021Review
- Graphene oxide and its derivatives as promising In-vitro bio-imaging platforms.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A nanotheranostics platform was synthesized based on PEGylated graphene oxide-gold nanoparticles and specified with aptamer toward the MUC-1-positive tumor cells. Subsequently, it was loaded with doxorubicin, used for non-invasive fluorescence imaging and therapy of breast and colon tumors. The success of the nano-coating at each synthesis step was characterized through FTIR, XRD, TGA, FE-SEM, EDAX, Zeta-potential, and fluorescence spectroscopy. Besides, the ability of the designed platform in targeted imaging, drug delivery, and in vitro therapy were evaluated using fluorescence microscopy and flow cytometry. The selected aptamer acts as a quencher, resulting in an "on/off" fluorescence biosensor. When the aptamer specifically binds to the MUC-1 receptor, its double strands separate, leading to the drug release and the recovery of the fluorescence of ("On" state) at the excitation wavelength of 300 nm. Based on cell toxicity results, this platform has more toxicity toward the MUC-1-positive tumor cells (HT-29 and MCF-7) compared to MUC-1-negative cells (Hep-G2), representing its selective performance. Thus, this nano-platform can be introduced as a multifunctional cancer nanotheranostics system for tracing particular biomarkers, non-invasive imaging, and targeted chemotherapy. Graphical abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.